Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

NCT04542369 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China